Vancouver, British Columbia - TheNewswire - September 13, 2021 - Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to provide an update on MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine. 

MindBio Therapeutics is excited to announce that it will open a world class facility providing research and drug development as a service to the pharmaceutical industry to potential clients in the United States and Canada. Companies in the psychedelic and pharmaceutical industry can now contract with MindBio Therapeutics for research and drug development on any psychedelic compound. Large pharmaceutical companies are increasingly looking to create synthetics compounds of psychedelics and MindBio Therapeutics has the ideal platform and access to infrastructure to help accelerate this activity.

With its exclusive agreement with the University of Auckland, MindBio has access to expansive infrastructure to bring psychedelic medicines to market. This includes research and drug development, ethical clinical expertise, clinical trial design, regulatory approvals, and formulation expertise. They have a multidisciplinary team with an interphase between medicines, psychiatry, and technology teams that can collaborate on building world class solutions for a wide range of mental health conditions. These facilities have neuroimaging technologies including EEG and MRI technology and have also opened a new clinic research centre including 30 clinical research rooms that is supported with world class pathology labs.

MindBio’s solution is cost effective, providing fast access to research and drug development infrastructure and can service clients globally. MindBio is already in discussions with several potential customers in the United States and sees a great opportunity for potentially generating ongoing revenue and licensing income from this new service offering.

About Blackhawk Growth

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.